First Time Loading...

Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.275 AUD -3.51% Market Closed
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

PAR Price Targets Summary
Paradigm Biopharmaceuticals Ltd

Wall Street analysts forecast PAR stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PAR is 1.36 AUD .

PAR Lowest Forecast
Wall Street Target
Not Available
PAR Average Forecast
Wall Street Target
1.36 AUD
395% Upside
PAR Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
1.36 AUD
395% Upside
Highest
Price Target
Not Available
Paradigm Biopharmaceuticals Ltd Competitors:
Price Targets
N
688105
Nanjing Vazyme Biotech Co Ltd
56% Upside
4978
ReproCell Inc
94% Upside
300639
Guangdong Hybribio Biotech Co Ltd
540% Upside
NTLA
Intellia Therapeutics Inc
220% Upside
N
688105
Nanjing Vazyme Biotech Co Ltd
56% Upside
4978
ReproCell Inc
94% Upside
300639
Guangdong Hybribio Biotech Co Ltd
540% Upside
NTLA
Intellia Therapeutics Inc
220% Upside
BONEX
Bonesupport Holding AB
35% Upside
KRYS
Krystal Biotech Inc
20% Upside
TNGX
Tango Therapeutics Inc
146% Upside
KRTX
Karuna Therapeutics Inc
2% Downside

Revenue
Forecast

Revenue Estimate
Paradigm Biopharmaceuticals Ltd

For the last 8 years the compound annual growth rate for Paradigm Biopharmaceuticals Ltd's revenue is 142%. The projected CAGR for the next 3 years is 103%.

142%
Past Growth
103%
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Paradigm Biopharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-13%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Paradigm Biopharmaceuticals Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-24%
Average Miss
What are analyst estimates?

See Also

Summary
PAR intrinsic value, competitors valuation, and company profile.
DCF Valuation
PAR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
PAR stock valuation using valuation multiples.
Wall Street Estimates
PAR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
PAR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is PAR's stock price target?
Price Target
1.36 AUD

According to Wall Street analysts, the average 1-year price target for PAR is 1.36 AUD .

What is Paradigm Biopharmaceuticals Ltd's Revenue forecast?
Projected CAGR
103%

For the last 8 years the compound annual growth rate for Paradigm Biopharmaceuticals Ltd's revenue is 142%. The projected CAGR for the next 3 years is 103%.

ALPHA SPREAD
Join more than 133,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.